Amplification of epidermal growth factor receptor (EGFR) and its active mutant EGFRvIII
occurs frequently in glioblastoma (GBM). While EGFR and EGFRvIII play critical roles in …

Glioblastoma (WHO grade IV astrocytoma) is the most frequent primary brain tumor in adults,
representing a highly heterogeneous group of neoplasms that are among the most …

Background Immunotherapies have demonstrated efficacy across a diverse set of tumors
supporting further evaluation in glioblastoma. The objective of this study was to evaluate the …

Glioblastoma (GBM) is the most common primary malignant brain tumor in adults.
Regardless of ideal multidisciplinary treatment, including maximal surgical resection …

Nowadays, due to recent advances in molecular biology, the pathogenesis of glioblastoma
is better understood. For the newly diagnosed, the current standard of care is represented by …

Abstract Background Depatuxizumab mafodotin (Depatux-M) is a tumor-specific antibody–
drug conjugate consisting of an antibody (ABT-806) directed against activated epidermal …

Simple Summary This review describes in a very detailed and exhaustive approach the
literature of these last 20 years on glioblastoma targeted therapies in Phases II-IV of 257 …

The receptor for epidermal growth factor (EGFR) is a prime target for cancer therapy across
a broad variety of tumor types. As it is a tyrosine kinase, small molecule tyrosine kinase …

Despite all of the progress in understanding its molecular biology and pathogenesis,
glioblastoma (GBM) is one of the most aggressive types of cancers, and without an efficient …

Translation of novel therapies for brain cancer into clinical practice is of the utmost
importance as primary brain tumors are responsible for more than 200,000 deaths …